Cited by 73Drug-Induced Hepatotoxicity and ProtectionPharmacology and Obesity TreatmentLiver Disease Diagnosis and Treatment

Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink

Open access
Douglas, I. J., Langham, J., Bhaskaran, K., Brauer, R., Smeeth, L.·2013·BMJ

Abstract

OBJECTIVE: To measure the association between orlistat and acute liver injury. DESIGN: Self controlled case series study. SETTING: Population based primary care setting, United Kingdom. PARTICIPANTS: 94,695 patients receiving orlistat and registered in the UK Clinical Practice Research Datalink and linked with Hospital Episode Statistics data between 1999 and 2011. MAIN OUTCOME MEASURE: Relative incidence of acute liver injury comparing periods when patients were receiving orlistat with periods of non-usage. RESULTS: Among 94,695 patients who received orlistat, 988 cases of acute liver injury were identified, with 335 confirmed as definite cases and 653 as probable cases. For all cases an increased incidence of liver injury was detected during the 90 day period before orlistat was first started, with an incidence rate ratio of 1.50 (95% confidence interval 1.10 to 2.06). The incidence remained raised during the first 30 days of treatment (2.21, 1.43 to 3.42), before returning to baseline levels with prolonged treatment. When the risk during the first 90 days of treatment was compared with the 90 days preceding first treatment, the incidence of liver injury was not increased (1.02, 0.67 to 1.56). An analysis restricted to definite cases showed no evidence of an increased risk of liver injury during treatment. CONCLUSION: The incidence of acute liver injury was higher in the periods both immediately before and immediately after the start of orlistat treatment. This suggests that the observed increased risks of liver injury linked to the start of treatment may reflect changes in health status associated with the decision to begin treatment rather than any causal effect of the drug.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.f1936

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The study used a self-controlled design where each participant acted as her own control to avoid potential confounding caused by differences between patients.

    “With this study design, each participant acted as her own control to avoid the potential confounding caused by differences between patients (16).”
  • The self-controlled design limited the effect of confounding associated with different distribution among patients of relevant characteristics that can influence study outcomes.

    “In this setting, participants acted as their own controls, thus limiting the effect of confounding associated with different distribution among patients of relevant characteristics that can influence study outcomes (16).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Douglas, I. J., Langham, J., Bhaskaran, K., Brauer, R., & Smeeth, L.
Affiliations
London School of Hygiene & Tropical Medicine (GB)
Corresponding author
Douglas, I. J.
Venue
BMJ
Publisher
BMJ
Published
2013-04-12
Volume
346
Issue
apr12 1
Pages
f1936-f1936
ISSN
1756-1833 (ISSN-L)
OpenAlex
W2135413686
Cited by
73
References
10
Citations by year
2026: 3 · 2025: 5 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 6 · 2020: 4 · 2019: 4 · 2018: 10 · 2017: 5 · 2016: 12 · 2015: 5 · 2014: 6 · 2013: 6
FWCI
10.44
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Wellcome Trust (098504)
  • National Institute for Health and Care Research (NF-SI-0510-10090, PDF-2011-04-007)
  • Medical Research Council (MR/K006584/1)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
Keywords
orlistat, acute liver injury, drug safety, hepatotoxicity, anti-obesity drugs, primary care, drug-induced liver injury
MeSH terms
Orlistat, Adult, Female, United Kingdom, Humans, Lactones, Male, Middle Aged, Obesity, Time Factors, Causality, Incidence, Case-Control Studies, Databases, Factual, Anti-Obesity Agents, Chemical and Drug Induced Liver Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review